311 related articles for article (PubMed ID: 21251686)
1. Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy.
Chang YH; Lin KD; He SR; Hsieh MC; Hsiao JY; Shin SJ
Metabolism; 2011 Aug; 60(8):1064-9. PubMed ID: 21251686
[TBL] [Abstract][Full Text] [Related]
2. Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects.
Ashley DT; O'Sullivan EP; Davenport C; Devlin N; Crowley RK; McCaffrey N; Moyna NM; Smith D; O'Gorman DJ
Metabolism; 2011 Jul; 60(7):994-1000. PubMed ID: 21087777
[TBL] [Abstract][Full Text] [Related]
3. Increased plasma osteoprotegerin concentrations in Type 1 diabetes with albuminuria.
Wang ST; Xu JM; Wang M; Chen FL; Ding G
Clin Nephrol; 2013 Mar; 79(3):192-8. PubMed ID: 23073066
[TBL] [Abstract][Full Text] [Related]
4. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy.
Moriwaki Y; Yamamoto T; Shibutani Y; Aoki E; Tsutsumi Z; Takahashi S; Okamura H; Koga M; Fukuchi M; Hada T
Metabolism; 2003 May; 52(5):605-8. PubMed ID: 12759891
[TBL] [Abstract][Full Text] [Related]
5. Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis.
Hofbauer LC; Schoppet M; Christ M; Teichmann J; Lange U
Rheumatology (Oxford); 2006 Oct; 45(10):1218-22. PubMed ID: 16574701
[TBL] [Abstract][Full Text] [Related]
6. Plasma osteoprotegerin concentrations in type 1 diabetic patients with albuminuria.
Elsamahy MH; Elhenawy YI; Nawar MM
J Diabetes Complications; 2015; 29(4):563-7. PubMed ID: 25744546
[TBL] [Abstract][Full Text] [Related]
7. The osteoprotegerin/tumor necrosis factor related apoptosis-inducing ligand axis in the kidney.
Candido R
Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):69-74. PubMed ID: 24247823
[TBL] [Abstract][Full Text] [Related]
8. Osteoprotegerin, trail and osteoprotegerin/trail ratio in patients at early phase of acute pancreatitis.
Dumnicka P; Zylka A; Kusnierz-Cabala B; Gurda-Duda A; Kuzniewski M; Drozdz R; Kulig J
Folia Med Cracov; 2014; 54(2):17-26. PubMed ID: 25648306
[TBL] [Abstract][Full Text] [Related]
9. Lovastatin raises serum osteoprotegerin level in people with type 2 diabetic nephropathy.
Nezami N; Safa J; Eftekhar-Sadat AT; Salari B; Ghorashi S; Sakhaee K; Khosraviani K
Clin Biochem; 2010 Nov; 43(16-17):1294-9. PubMed ID: 20727867
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
[TBL] [Abstract][Full Text] [Related]
11. Elevated levels of TRAIL in systemic lupus erythematosus are associated to the presence of anti-SSA/SSB antibodies.
Castellino G; Corallini F; Trotta F; Secchiero P
Lupus; 2007; 16(7):479-82. PubMed ID: 17670845
[TBL] [Abstract][Full Text] [Related]
12. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction.
Secchiero P; Corallini F; Pandolfi A; Consoli A; Candido R; Fabris B; Celeghini C; Capitani S; Zauli G
Am J Pathol; 2006 Dec; 169(6):2236-44. PubMed ID: 17148684
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes.
O'Sullivan EP; Ashley DT; Davenport C; Devlin N; Crowley R; Agha A; Thompson CJ; O'Gorman D; Smith D
Diabetes Metab Res Rev; 2010 Sep; 26(6):496-502. PubMed ID: 20809534
[TBL] [Abstract][Full Text] [Related]
14. Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas.
Sandra F; Hendarmin L; Nakamura S
Oral Oncol; 2006 Apr; 42(4):415-20. PubMed ID: 16413220
[TBL] [Abstract][Full Text] [Related]
15. Osteoprotegerin (OPG) and TNF-related apoptosis-inducing ligand (TRAIL) levels in malignant and benign pericardial effusions.
Karatolios K; Pankuweit S; Goettsch C; Hofbauer LC; Timmesfeld N; Al-Fakhri N; Maisch B; Schoppet M
Clin Biochem; 2012 Feb; 45(3):237-42. PubMed ID: 22202560
[TBL] [Abstract][Full Text] [Related]
16. Plasma osteoprotegerin concentrations in peripheral sensory neuropathy in Type 1 and Type 2 diabetic patients.
Nybo M; Poulsen MK; Grauslund J; Henriksen JE; Rasmussen LM
Diabet Med; 2010 Mar; 27(3):289-94. PubMed ID: 20536491
[TBL] [Abstract][Full Text] [Related]
17. Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor-alpha and interleukin-6 in type 2 diabetic patients.
Navarro JF; Mora C; Gómez M; Muros M; López-Aguilar C; García J
Nephrol Dial Transplant; 2008 Mar; 23(3):919-26. PubMed ID: 17911088
[TBL] [Abstract][Full Text] [Related]
18. Elevation of urinary betaig-h3, transforming growth factor-beta-induced protein in patients with type 2 diabetes and nephropathy.
Ha SW; Kim HJ; Bae JS; Jeong GH; Chung SC; Kim JG; Park SH; Kim YL; Kam S; Kim IS; Kim BW
Diabetes Res Clin Pract; 2004 Aug; 65(2):167-73. PubMed ID: 15223229
[TBL] [Abstract][Full Text] [Related]
19. Association between serum fibroblast growth factor 21 and diabetic nephropathy.
Jian WX; Peng WH; Jin J; Chen XR; Fang WJ; Wang WX; Qin L; Dong Y; Su Q
Metabolism; 2012 Jun; 61(6):853-9. PubMed ID: 22136913
[TBL] [Abstract][Full Text] [Related]
20. The effect of exercise on osteoprotegerin and TNF-related apoptosis-inducing ligand in obese patients.
Davenport C; Kenny H; Ashley DT; O'Sullivan EP; Smith D; O'Gorman DJ
Eur J Clin Invest; 2012 Nov; 42(11):1173-9. PubMed ID: 22803952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
